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Abstract
Background: Reduced CD4 T lymphocytes counts can be observed in HIV infection and in patients undergoing autologous
haematopoietic stem cell transplantation (ASCT). Nevertheless, whereas opportunistic infections (OI) are frequent in HIV-
infected individuals with low cell counts, OI are uncommon in ASCT patients.
Methodology/Principal Findings: To verify whether this observation could be secondary to intrinsic HIV-correlated T cell
defects, we performed in-depth immunologic analyses in 10 patients with comparable CD4 counts in whom lymphopenia
was secondary either to HIV-infection or ASCT-associated immunosuppressive therapy and compared them to age-matched
healthy subjects. Results showed the presence of profound alterations in CD4+ T lymphocytes in both groups of patients
with respect to healthy controls. Thus, a low percentage of CCR7+ CD4+ T cells and a compensative expansion of
CD45RA2CCR72 CD4+ T cells, a reduced IL-2/IFN-c cytokine production and impaired recall antigens-specific proliferative
responses were detected both in ASCT and HIV patients. In stark contrast, profound differences were detected in CD8+ T-
cells between the two groups of patients. Thus, mature CD8+ T cell prevailed in ASCT patients in whom significantly lower
CD45RA2CCR72 cells, higher CD45RA+CCR72 CD8+ cells, and an expansion of CCR7+CD8+ cells was detected; this
resulted in higher IFN-c +/TNFa production and granzyme CD8+ expression. The presence of strong CD8 T cells mediated
immune responses justifies the more favorable clinical outcome of ASCT compared to HIV patients.
Conclusion/Significance: These results indicate that CD8 T cells maturation and functions can be observed even in the face
of a profound impairment of CD4+ T lymphocytes in ASCT but not in HIV patients. Primary HIV-associated CD8 defects or an
imprinting by an intact CD4 T cell system in ASCT could justify these results.
Citation: Bandera A, Trabattoni D, Pacei M, Fasano F, Suardi E, et al. (2008) Fully Immunocompetent CD8+ T Lymphocytes Are Present in Autologous
Haematopoietic Stem Cell Transplantation Recipients Despite an Ineffectual T-Helper Response. PLoS ONE 3(10): e3616. doi:10.1371/journal.pone.0003616
Editor: Derya Unutmaz, New York University School of Medicine, United States of America
Received May 27, 2008; Accepted October 9, 2008; Published October 31, 2008
Copyright:  2008 Bandera et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The present study was funded by a grant from Ermenegildo Zegna Foundation, Italy, and AHSI Company, Milan, Italy. The funders supported the study
and concorded with the authors about the design and the management of the study.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: a.bandera@hsgerardo.org
Introduction
High-dose chemotherapy followed by autologous stem cell
transplantation (ASCT) has become an established treatment option
for various malignancies [1,2]. Although stem cell transplantation is
believed to shorten the early period of severe neutropenia, recipients
of ASCT suffer from a prolonged posttransplant immune deficiency,
most pronounced inT-cell lineage, and cellular immunity remaining
ineffective for several months after transplantation [3,6]. Consider-
ing infectious complications, the early period of neutropenia is
frequently complicated by bacterial episodes, but after neutrophils
recovery, despite the persistent impairment of CD4+ cells and
cellular specific immunity, the risk of developing opportunistic
infections in ASCT patients is low [7–10]. In contrast to what is
observed in ASCT recipients, the impairment in CD4+ T-cells in
HIV infection, although in many cases less severe compared to
ASCT, correlates with the risk of developing viral, fungal and
bacterial infections, and a CD4+ count less of 200/mL is necessarily
associated with major opportunisms development, AIDS-defining
illnesses and death [11].
It follows that, since CD4+ T cells lymphopenia is not
considered to be an univocal marker of risk for opportunistic
infections, it is likely that various qualitative parameters of immune
response play important roles. Interestingly, such a disease model,
characterized by a discrepancy between T lymphocytes numbers
and functions, was described early on in HIV research [12,13].
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has been observed in HIV-infected patients, involving defective
memory cell production and increasing defects in effector cell
function, in conjunction with lack of antigen clearance [14–19].
Additionally, a selective loss of HIV-1 specific central memory
CD4+ T cells, associated with an expanded monophenotypic
CD4+ CD45RA2CCR72 response has been demonstrated, and
there is strong evidence of the development of antigen-specific
CD8+ T cells biased towards an effector, rather than a central
memory phenotype. These phenotypic findings have been
associated with the lack of control of the immune system on viral
replication, owing to the fact that, in HIV infection,
CD45RA2CCR72 CD4+ T cells are functionally characterized
by low-IL-2/high interferon(IFN)-c production and minimal
proliferative ability, and CD45RA2CCR72 CD8+ T cells are
endowed with lower content of lysis molecules, low proliferative
ability, and altered cytokine production and ability [20–26].
Limited information is available regarding the phenotypic and
functional heterogeneity of CD4+ and CD8+ T cells regenerating
after high dose chemotherapy and ASCT; and to date no
comprehensive characterization of maturative patterns has risen
in these patients. The aim of our study was to compare phenotypic
and functional patterns of T-cells in ASCT recipients and in HIV-
infected subjects, with comparable CD4+ lymphopenia but with
starkly contrasting infectious risks.
Results
Study groups
Ten age-matched subjects with comparable CD4+ lymphopenia
were recruited: 5 cancer patients receiving ASCT 9 months before
observation (ASCT) and 5 HIV+ antiretroviral naı ¨ve subjects
(HIV). Demographic and clinical data are presented in Table 1.
According to institutional review board-approved chemotherapy
protocols, high-dose chemotherapy for cancer patients consisted of
ICE, ifosfamide (12 g/m
2), carboplatin (1800 mg/m
2) and etopo-
side (2 g/m
2), for breast cancer patients (n=2) and melphalan
(cumulative dose 200 mg/m
2) for multiple myeloma patients
(n=3). Febrile neutropenia was observed in 4/5 (80%) ASCT
recipients during pre-engrafment phase and has been treated with
large-spectrum empiric antibiotic. No opportunistic infections
were observed in ASCT recipients until time of the analysis. Of
HIV-infected patients, 4/5 had opportunistic infections during the
six months previous to observation (2 patients esophageal
candidiasis, 1 patient bacterial pneumonia and oropharingeal
candidiasis and 1 patient thoracic VZV and oropharingeal
candidiasis). Sulphamethoxazole/trimethoprim was administered
as Pneumocystis jiroveci pneumonia prophylaxis to ASCT recipients
and HIV-infected subjects with less than 200/mL CD4+ at
observation. At time of the analysis, ASCT recipients and HIV-
infected patients displayed comparable CD4+ absolute number
and percentage: ASCT recipients 230/ml (range 164–300), 16%
(range 10–25); HIV+ 255/ml (range 189–300), 17% (range 11–20)
(p.0.05). CD8 lymphocytes absolute count and percentage did
not show significant differences between the two groups: ASCT
recipients 670/ml (range 496–919), 54% (range 48–69); HIV+
658/ml (range 540–823), 51% (range 47–62) (p.0.05).
Comparison of lymphocytes subsets phenotype and func-
tional studies was made to data obtained from age-matched
healthy subjects (n=5) used as controls (HC), who displayed
CD4+ and CD8+ absolute count and percentage within the
normality range: CD4+ 1098/ml (range 797–2365), 45%
(range 35.9–66.9); CD8+ 475 (range 447–628), 18.3% (range
17.7–21.3).
CD4+ lymphocytes maturation patterns are skewed in
ASCT recipients and in HIV-infected patients
We investigated phenotypical maturation pattern of lympho-
cytes in ASCT recipients and in HIV patients, analyzing cells
based on the expression of CD45 isoforms and chemokine
receptor CCR7. Despite contrasting clinical risk, ASCT recipients
displayed a skewed CD4+ phenotype distribution very similar to
what observed in HIV-infected subjects (Fig. 1). Indeed, the
fraction of naı ¨ve CD4+ T cells (CD45RA+CCR7+) was signifi-
cantly lower in both population compared to healthy controls
(ASCT, 5.49%; HIV, 8.13%;HC, 35,9%; p,0.05 for HC versus
ASCT and HIV; p.0.05 for ASCT versus HIV). Moreover, an
expansion of effector memory CD45RA2CCR72 cells was seen both
in ASCT and in HIV-infected patients with respect to age-
matched healthy subjects (ASCT 62.6%; HIV 62.3%; HC 27.8%;
p,0.05 for HC versus ASCT and HIV; p.0.05 for ASCT versus
HIV), while ASCT recipients displayed the highest levels of effector
CD45RA+CCR72 cells (ASCT 11.2%, HIV 2.18%, HC 1.89,
p, 0.05 for ASCT versus HC, p.0.05 for ASCT versus HIV).
Central memory cells (CD45RA2CCR7+), which have been
recognized as the predominant CD4+ subpopulation in healthy
controls together with naı ¨ve CD4+ T cells, were evidenced at lower
frequency in ASCT recipients (8.48%) and HIV-infected subjects
(17.9%), with statistical significance in the comparison between
ASCT patients and healthy subjects (ASCT 8.48%, HIV 17.9%,
Table 1. Characteristics of the ASCT (Group A) and HIV-
infected patients (Group B).
Group A Group B p
(n=5) (n=5)
Inclusion criteria
CD4+ counts (cell/mL) ,300 ,300
Actual opportunistic infections No No
Current HAART Non applicable No
Neoplasia’s relapse No Non applicable
Baseline characteristics
Age (years)
median 48 43 ns
range 40–59 36–60
Actual CD4+ T cells/mL
median 255 230 ns
range 189–300 164–300
Actual CD4+ %
median 17 16 ns
range 11–20 10–25
Actual CD8+ T cells/mL
median 658 670 ns
range 540–823 496–919
Actual CD8+ T%
median 51 54 ns
range 47–62 48–69
CD4/CD8 ratio
median 0.34 0.29 ns
range 0.24–0.52 0.15–0.58
doi:10.1371/journal.pone.0003616.t001
Lymphocytes in ASCT and HIV
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ASCT and HC). Similarly to what observed in HIV-infected
patients, ASCT recipients present a phenotypic CD4+ pattern
characterized by a relative expansion of effector memory cells and a
loss of central memory cells, which has been hypothesized
disadvantageous in chronic infections.
CD8+ maturation patterns are preserved in ASCT
recipients compared to HIV-infected patients
A wholly different scenario was evidenced when CD8+ T cell
maturation patterns were analyzed in ASCT recipients and in
HIV-infected subjects (Fig. 2). Indeed, while ASCT recipients
displayed levels of CD45RA+CCR7+ CD8+ T-cells comparable
with healthy controls (ASCT 28.83%; HIV 26.9%; p.0.05),
significant reduced levels of naı ¨ve CD8 T cells were seen in HIV+
patients (6.07%, p,0.05 for HIV versus HC). Moreover, while
CD45RA2CCR72 CD8+ T cells predominated in HIV positive
patients, levels of these pre-terminally differentiated cells were
significantly lower in ASCT recipients and in healthy controls
(ASCT 36.4%, HIV 62.6%, HC 32.3%, p,0.05 for HIV versus
ASCT and HC). Higher levels of CD45RA+CCR72 effector CD8+
cells were present in ASCT recipients than in HIV-infected
subjects (ASCT 21.07%, HIV 12.55%, p=0.05), who displayed
significantly lower levels of terminal differentiated CD8+ T cells
compared to healthy controls (HC 33.2%, p,0.05 for HIV versus
HC). These data demonstrate that, unlike the chronic viral model,
in ASCT recipients the rapidly replicating CD8+ T cell
compartment follow a phenotypic distribution biased toward a
terminally differentiated effector cell phenotype.
A low effector memory/terminally differentiated CD8+
ratio characterizes ASCT recipients
To characterize the imbalance between T cells with different
maturative phenotype, we calculated ratios of various subsets of
CD4+ and CD8 lymphocytes across the two groups of patients.
Ratios between CD4+ subpopulation, CD45RA2CCR7+/
CD45RA2CCR72,C D 4 5 R A 2CCR72/CD45RA+CCR72
and CD45RA2CCR72/CD45RA+CCR72 evaluated for ASCT
recipients failed to uncover significant differences compared to HIV-
infected patients (0.12 versus 0.23, 6.83 versus 10.81, 0.57 versus
2.84 respectively). However, the comparison of ASCT recipients
with age-matched healthy controls showed significantly low ratios
Figure 1. Phenotypical maturation pattern of CD4+ lymphocytes in ASCT recipients (ASCT), HIV-infected patients (HIV) and healthy
controls (HC). The percentage of naı ¨ve CD4+ T cells (CD45RA+CCR7+) (A), central memory (CD45RA2CCR7+) (B), effector memory (CD45RA2CCR72)
(C) and effector cells (CD45RA+CCR72) (D) were compared in the groups. ASCT recipients and HIV-infected patients displayed low percentages of
naı ¨ve and central memory CD4+ T cells. A relative expansion of effector memory cells was observed in both population. Each central bar represents the
median value and each box corresponds to the 25
th through 75
th percentile (interquartile) range.
doi:10.1371/journal.pone.0003616.g001
Lymphocytes in ASCT and HIV
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ASCT patients, thus confirming the skewed representation of
repopulating memory CD4+ Tc e l l s .
In stark contrast, the CD45RA2CCR72CD8+ and
CD45RA+CCR72CD8+ ratio was significantly higher in HIV+
patients compared to ASCT recipients, who displayed values
similar to healthy controls (ASCT 1.83, HIV 5.77, HC 0.97,
p,0.05 for HIV versus ASCT and HC). This observation
underlines the over-representation of pre-terminally differentiated
CD8+ T cells and the simultaneously lower levels of terminally
differentiated CD8+ T cells in HIV population (Fig. 3).
Cytokine CD4+ production is impaired in both ASCT
recipients and HIV-infected patients
To determine whether the relevant phenotypic characteristics
are associated with selective defects in cytokine production in
ASCT recipients compared to HIV-infected subjects, we tested the
capacity of CD4+ T cells to produce IL-2 and IFN-c in response to
superantigen stimulation (fig. 4A). Profound impairment in IL-2
and IFN-c production after SEB stimulation was found in both
group of patients with respect to age-matched healthy controls (IL-
2+/CD4+ ASCT 1.18%, HIV 0.4%, HC 5.28%, p,0.05 for HC
versus ASCT and HIV; IFN-c+/CD4+ ASCT 0.96%, HIV 1.2%,
HC 2.59%, p=ns).These observations suggest that CD4+ T cells
activated via T-cell receptor stimulation are dramatically weak-
ened in their capacity to produce IL-2 and IFN-c, both in ASCT
recipients and in HIV disease.
Cytokine CD8+ production is observed in ASCT recipients
but not in HIV-infected patients
In ASCT recipients, cytokine expression analysis for CD8+ T-
cells produced a very different picture with respect to the HIV
population (fig. 4B). Compared to HIV-infected patients, in fact,
ASCT recipients showed significantly higher levels of TNF-a and
IFN-c producing CD8+ T cells (2.27% versus 0.3% and 2.00%
versus 0.35% respectively, p,0.05). Moreover, differences were
detected in cytokine production after SEB stimulation: CD8+
lymphocytes from ASCT recipients displayed significantly higher
production of TNFa than those of HIV-infected patients (2.27%
versus 0.45%, p,0.05) reaching levels similar to healthy controls
Figure 2. CD8+ T cell maturation patterns lymphocytes in ASCT recipients (ASCT), in HIV-infected patients (HIV) and healthy
controls (HC). The percentage of naı ¨ve CD8+ T cells (CD45RA+CCR7+) (A), central memory (CD45RA2CCR7+) (B), effector memory (CD45RA2CCR72)
(C) and effector cells (CD45RA+CCR72) (D) were compared in the groups. Higher levels of naı ¨ve CD8+ T-cells were observed in ASCT recipients
compared to HIV+ patients. Whereas in HIV positive patients effector memory CD8+ T cells were the predominant memory phenotype, in ASCT
recipients significantly higher levels of CD45RA+CCR72 effector CD8+ cells were evidenced. Each central bar represents the median value and each
box corresponds to the 25
th through 75
th percentile (interquartile) range.
doi:10.1371/journal.pone.0003616.g002
Lymphocytes in ASCT and HIV
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ASCT and HC), despite comparable IFN-c levels (ASCT 1.22%,
HIV 3.05%, HC 4.04%, p=ns).
Granzyme B expression
To better characterize the functional properties of cytotoxic cells,
we additionallyassessed by flowcytometry granzymeB expression in
CD8+ T cells from ASCT recipients and HIV-infected subjects
compared to healthy controls. Our results were consistent with those
obtained using CD45RA/CCR7 co-expression, since the amounts
of CD8+ T cells expressing granzyme B were many fold higher in
ASCT recipients than in HIV-infected patients (ASCT 73.9%, HIV
22.3%, p,0.05) both in basal conditions and after SEB stimulation
(ASCT 67.4%,HIV 26.8%, p,0.05) with no significant differences
compared to age-matched healthy controls (basal 89.7%, after SEB
stimulation 88.7%, p,0.05 for HC versus HIV, p.0.05 for HC
versus ASCT)(fig. 4C). These findings correlate nicely with the
phenotypic pattern described in ASCT recipients, considering that
expression of granzyme B is a specific characteristic of mature
effector CD8+ Tc e l l s .
Lymphocyte proliferation
Finally, in order to investigate lymphocyte function, we
analyzed lymphocyte proliferation in ASCT-recipients and in
HIV-infected patients (fig. 4D). Antigen-induced proliferative
responses were depressed in all patients with respect to age-
matched healthy controls, reaching statistical significance for FLU
stimulation (median stimulation index values: PHA ASCT 1.89,
HIV 2.03, HC 2.69; FLU ASCT 1.55,HIV 1.02, HC 1.97,
p,0.05 for HC versus HIV, Candida albicans ASCT 1.98,HIV
1.37, HC 1.40). One explanation for these observations could be
that lymphoproliferation is primarily a function of T CD4+ cells,
the numbers and functional capabilities of which were comparably
depressed in both group of patients.
Discussion
Delayed immune reconstitution remains one of the least
understood issues among the many clinical challenges facing
ASCT clinicians, and the clinical significance of profound and
persistent CD4+ T cells lymphopenia, although often unassociated
with opportunistic infections, has yet to be fully defined [27]. In
patients with HIV infection, on the other hand, the selective loss of
CD4+ T cells apparently triggers profound immunodeficiency,
often leading to fatal infection, AIDS-defining illnesses and,
ultimately, death [11]. To verify if the differing qualitative aspects
of immune response characterizing CD4+-lymphopenic patients
subjected to ASCT, with respect to those of HIV-infected patients,
could account for the differences in infectious risks between the
two groups, we phenotypically and functionally analyzed CD4+
and CD8+ lymphocytes in ASCT or HIV patients with
comparable CD4 counts.
Our results demonstrate that patients undergoing high dose
chemotherapy and ASCT have a persistent, marked deficit in
CD4+ T-cell function. And yet, in contrast to HIV-infected
subjects, such individuals are characterized by a CD8 T-cell
compartment that is phenotipically normal and functionally active.
An alteration of the CD4/CD8 ratio, secondary to CD4+ T
cells decrease and largely sustained by a loss of CD4+ naı ¨ve T cells,
has often been described in different cohorts of ASCT recipients
[3–5].
Our study confirms the profound loss of naı ¨ve CD4+ T cells in
patients treated with high-dose chemotherapy and ASCT.
Moreover, we show that the remaining CD4+ T compartment is
constituted by T cells which have a memory phenotype, but which
are skewed toward the later stages of differentiation, a character-
istic typical of HIV infection. Central memory and effector CD4+
cells in fact were decreased both in HAART- naı ¨ve HIV-infected
and in ASCT patients in whom a massive expansion of
Figure 3. Ratios of CD4+ and CD8+ lymphocytes subsets across ASCT recipients (ASCT), HIV-infected patients (HIV) and healthy
controls. ASCT recipients and HIV-infected patients displayed similar ratios between CD4+ subpopulations, CD45RA2CCR7+(CM)/CD45RA2CCR72
(EM). CD45RA2CCR72CD8+(EM)/CD45RA+CCR72CD8+(TD) ratio was significantly lower in ASCT recipients compared to HIV+ patients, with no
differences in CD45RA2CCR7+ CD8+ (CM)/CD45RA2CCR72 CD8+ (EM) and CD45RA2CCR7+ CD8+ (CM)/ CD45RA+CCR72CD8+ (TD) ratios among
the two group of patients.
doi:10.1371/journal.pone.0003616.g003
Lymphocytes in ASCT and HIV
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This phenotypic data well correlate with the results of our
functional analysis, characterized by low IL-2/IFN-c producing
CD4 T lymphocytes of highly impaired proliferative ability.
In chronic viral infections, phenotypic and functional hetero-
geneity of memory CD4 T cells responses is believed to be
regulated by antigen persistence and high/low levels of antigen
load. The monophenotypic CD45RA2CCR72 CD4 T cell
responses typical of chronic and progressive HIV infection have
not, in fact, been found in long term non-progressors, where a
multi-phenotypic CD4 T cell response, typical of repetitive Ag
exposure and low Ag load was present [16,23].
It is well known that lymphopenia is invariably associated with
homeostatic expansion of the remaining T cells in the periphery,
in response to endogenous MHC ligands and IL-7, but also with
immune reactivity, both to self- and foreign antigens not normally
apparent in T cell–replete hosts [28]. Consequentially, the
explanation for the large compensative expansion of monopheno-
typic CD45RA2CCR72 CD4 T cell responses in ASCT recipients
could be a high antigenic exposure to self peptide, including tumor
antigens [29], or, alternatively, to nonself peptides, such as normal
flora in the gastrointestinal [GI] tract–gut commensals, that have
been recognized as the dominant force for rapid proliferation of T
cells in severely immunodeficient host [28].
In summary, our data show that CD4+ T-cell count deficiency
in ASCT recipients is associated with skewed representation of
memory CD4 T cells and cytokine and proliferative defects - an
immune pattern surprisingly similar to that of HIV infection. In
contrast to HIV-positive patients, however, CD8 T cells were
normally distributed and were functionally intact in ASCT
recipients 9 months after. The presence of high quantities of
TNFa/IFNc-producing and granzyme-enriched effector CD8+ T
cells, associated with the low rate of infectious mortality observed
in ASCT recipients [8], suggest that even a T-cell compartment
which is greatly impaired in CD4+ T cells number and function
may provide protective immunity against opportunistic agents if it
Figure 4. Cytokine CD4+ (A) and CD8+ (B) production, CD8+ lysis molecules expression (C) and lymphocyte proliferation (D) in
ASCT recipients (ASCT), in HIV-infected patients (HIV) and in healthy controls (HC). ASCT recipients displayed significantly higher levels of
TNF-a and IFN-c producing CD8+ T cells under basal conditions and of TNF-a+ CD8+ T cells under Staphylococcal b enterotoxin (SEB) stimulation
compared to HIV-infected patients. CD4+ IL-2 and IFN-c production after SEB stimulation was globally depressed in both group of patients compared
to healthy controls. The fraction of CD8+ T cells expressing granzyme B was higher in ASCT recipients than in HIV-infected patients. Antigen-induced
proliferative responses showed comparable stimulation index values in both patients population and for polyclonal activation (PHA) as well as
antigen stimulation (Flu, Candida), with significant difference with healthy controls regarding Flu stimulation. *=p,0.05 in the comparison between
groups.
doi:10.1371/journal.pone.0003616.g004
Lymphocytes in ASCT and HIV
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protective effect of CD8+ T cells is supported by extensive clinical
studies on HSCT patients. Analysis of immune reconstitution in
both autologous or allogenic stem cell transplantation recipients
showed that autologous recipients presented less viral reactivation
associated with more vigouros CD8+-effector specific immune
response [6]. Conversely, HIV-infected patients, as confirmed by
our study, are characterized by the accumulation of pre-TD CTL,
which phenomenon has been linked to the lack of control of the
immune response on HIV replication in infected patients. It is
therefore arguable that in a CD4+-lymphopenic setting, preser-
vation of CD8+ effector function may be essential in the
prevention of opportunistic infections.
Our observations indicate that although overall T CD4+ cell
number and function are significantly reduced in ASCT recipients,
the CD8+ T cell compartment is relatively well preserved. As
animal models have elegantly shown, memory CD8 T cells
generated in the presence of CD4 T cells gave the same robust
secondary response after transfer into CD4-deficient or CD4-
competent hosts [30]. Given the low rate of infectious mortality in
ASCT patients, our data suggest that a CD8+ effector function,
originally imprinted by a preserved CD4+ T cells system, might
provide a clinically meaningful degree of protective immunity even
in the absence of actual T-helper supports.
In conclusion, our study, even with limited data, confirms the
substantial difference in both quantitative and functional regener-
ation of CD4+ and CD8+ cells after ASCT, providing strong
evidence of a protective roleplayed by differentiatedT CD8+ cells in
combating opportunistic infections and viral reactivation. We think
that this issue together with the reasons of the skewed representation
of memory CD4 T cells and cytokine and proliferative defects
present in ASCT recipients should be explored more extensively in
larger studies. In progressive HIV-infection, interventions aimed at
expanding CD8+ T cell activity in the early phase of infection, when
CD4 and CD8 T cell function is relatively preserved, may be an
effective approach to improving global immunity and preventing
opportunistic infections in advanced phase of immune-deficiency.
Overall, these findings could provecritical inthe clinical follow-up of
ASCT recipients and for the design of vaccines in this population.
Materials and Methods
Study design
We performed a cross-sectional, observational, institutional
review board-approved study of ASCT recipients and HIV-
infected subjects attending the Chair of Infectious Diseases and
Tropical Medicine–University of Milan, Italy.
Ten age-matched patients with comparable CD4+ lymphopenia
(CD4+,300/mL) were enrolled according with the following
definition: (i) neoplastic patients (breast cancer and multiple
myeloma) (n=5) receiving ASCT 9 months before observation,
without neoplasia’s relapse and free from opportunistic infections;
(ii) HIV-infected patients (n=5) naı ¨ve for antiretroviral therapy,
stage B3 or C3 according to CDC ‘93 classification. Exclusion
criteria were patients with recurrence of tumor or re-introduction
of chemotherapy within 9 months after ASCT, patients with
primary HIV infection defined as confirmed, recent HIV-1
infection by documented seroconversion illness and incomplete
Western blot or a negative test within the previous 6 months, and
previous treatment with cytokines or immunomodulants.
Comparison of lymphocyte subset phenotype and function was
made to a data set obtained from 5 healthy controls aged 32 to 52
years (median 47 years) provided by the Chair of Infectious
Disease and Tropical Medicine- University of Milan, Italy.
Patients and healthy controls participating in this study gave
written informed consent according to the Declaration of Helsinki.
Flow cytometric analysis. Peripheral cells were washed in
PBS and stained for 30 min at 4uC in the dark with the following
antibodies: CD4 Cy5PE (mouse IgG2a isotype, Caltag); CD8
Cy5PE (mouse IgG2a isotype), CD8 FITC (mouse IgG2a isotype);
CD45RA FITC (mouse IgG2b isotype); CCR7 PE (mouse IgG2a
isotype, R&D Systems, Minneapolis, MN). Cells used for
intracellular molecule staining were washed and fixed in Reagent
A solution (FIX & PERM cell permabilization Kits; Caltag) for
10 min at room temperature in the dark. The cells were washed
onceagain inPBSand resuspended inReagent B (FIX& PERM cell
permabilization Kits; Caltag) with cytokine- or perforin/granzyme-
specificmonoclonal antibodies(IL-2PE;mouseIgG2a isotype;IFNc
FITC; mouse IgG1 isotype; TNF-a PE; mouse IgG2a isotype;
granzyme B PE, mouse IgG1 isotype; Caltag Laboratories; perforin
FITC; mouse IgG2b isotype; Ancell, Bayport, MN). The cells were
then fixed in 1% paraformaldehyde in PBS.
Cytometric analyses were performed using an EPICS XL flow
cytometer (Beckman-Coulter Inc., Miami, FL) equipped with a
single 15 mW argon ion laser operating at 488 nm interfaced with
486 DX2 IBM computer (IBM, Cambridge, UK). For each
analysis, 200,000 events were acquired. Green florescence from
FITC (FL1) was collected through 525-nm bandpass filter and
deep-red fluorescence from Cy5PE (FL4) was collected through
670-nm bandpass filter. Data were collected using linear amplifiers
for forward and side scatter and logarithmic amplifiers for FL1
and FL4. Samples were first run using isotype controls or single
fluorochrome-stained preparations for color compensation. The
EPICS XL Coulter is 4-colour flow cytometer and a CD3 ECD
mAb was used to gate T cells. Moreover, to be sure to identify only
CD8+ T cells we analysed only CD8
bright cells that are CTLs,
excluding CD8
dim cells which include NK cells.
Cytokine and perforin/granzyme production. PBMC
were incubated for 18 hours with medium or Staphylococcal b
enterotoxin (SEB) (5 mg/ml) (Sigma, St. Louis, MO). CD28
antibody (Clone 37407.111; R&D Systems, Minneapolis,
Minnesota, USA) was added during incubation (1 mg/well) to
facilitate co-stimulation. For cytokine and peforin/granzyme
analyses 10 mg/ml Brefeldin A (Sigma, St. Louis, Missouri, USA)
were added to the cell cultures during the last 6h of stimulation to
blockproteinsecretion.Analyseswereperformedonfreshlycollected
cells. SEB concentration utilized in this study was tested to not
induce cell death after overnight incubation. However, cells were
analysed for vitality (blue trypan exclusion method) before ICC
staining procedure.
Proliferative tests. PBMCs (3610
5) were placed in round-
bottom wells of a microtiter culture plate (COSTAR, Cambridge,
MA) in a final volume of 0,2 ml in the presence/absence of
influenza virus vaccine prepared with a mixture of A/Taiwan, A/
Shangai, and B/Victoria (FLU) (24 mg/ml); phytoemoagglutin
(PHA) (2,5 mg/ml) (Sigma, St. Louis, MO); or Candida Albicans
antigen (CAN) (1,6 mg/ml) (Green Laboratories, USA). Three
replicate cultures were performed for each stimulation. Pooled
human plasma (10%) were added to each well. We stimulated cells
for 3 days to analyze lymphoproliferative responses to PHA and
for 6 days to FLU vaccine prep and Candida albicans.
After incubation at 37uC and 7% CO2, cultures were pulsed
with 1 mCi of [3H]-thymidine and harvested 18 h later.
Incorporated [3H]thymidine was measured with a liquid scintil-
lation beta counter. Results were expressed as mean counts per
minute. The stimulation index represents the ratio of mean counts
obtained in the presence of antigen to mean counts obtained
without antigen.
Lymphocytes in ASCT and HIV
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Procedures were based on non parametric analyses (Mann-
Whitney); comparisons between the different groups were made
using a two-tailed T-test. Statistical analysis was performed using
the SPSS statistical package (SPSS Inc. Chicago, Illinois, USA).
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